Beigene LtdNASDAQ:BGNE
- LAST PRICE156.3600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 156.3600
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BGNE |
|---|---|---|
| 09:32 ET | 849 | 157.6 |
| 09:39 ET | 119 | 156.85 |
| 09:59 ET | 300 | 158.525 |
| 10:03 ET | 100 | 158.39 |
| 10:08 ET | 100 | 158.17 |
| 10:15 ET | 100 | 158.39 |
| 10:21 ET | 110 | 158.93 |
| 10:26 ET | 100 | 158.8 |
| 10:39 ET | 100 | 158.875 |
| 10:42 ET | 100 | 159.145 |
| 10:50 ET | 600 | 159.355 |
| 10:51 ET | 500 | 159.16 |
| 10:57 ET | 100 | 159.115 |
| 11:04 ET | 1700 | 158.515 |
| 11:06 ET | 100 | 158.425 |
| 11:08 ET | 200 | 158.21 |
| 11:22 ET | 100 | 158.18 |
| 11:24 ET | 100 | 158.47 |
| 11:26 ET | 225 | 158.51 |
| 11:29 ET | 380 | 158.865 |
| 11:31 ET | 1000 | 158.63 |
| 11:38 ET | 100 | 158.75 |
| 11:51 ET | 143 | 158.7868 |
| 12:02 ET | 548 | 158.745 |
| 12:03 ET | 200 | 158.765 |
| 12:05 ET | 202 | 158.59 |
| 12:07 ET | 100 | 158.245 |
| 12:09 ET | 400 | 158.48 |
| 12:27 ET | 500 | 158.5 |
| 12:32 ET | 14100 | 158.125 |
| 12:34 ET | 200 | 158.085 |
| 12:43 ET | 200 | 157.795 |
| 12:54 ET | 1100 | 157.93 |
| 12:56 ET | 100 | 157.915 |
| 12:57 ET | 100 | 158.115 |
| 01:01 ET | 200 | 158.09 |
| 01:15 ET | 100 | 158.05 |
| 01:17 ET | 100 | 158.07 |
| 01:26 ET | 236 | 157.99 |
| 01:46 ET | 100 | 158.13 |
| 01:48 ET | 150 | 158.0487 |
| 01:50 ET | 100 | 158.16 |
| 01:53 ET | 100 | 158.0425 |
| 02:02 ET | 300 | 157.9 |
| 02:04 ET | 100 | 158.13 |
| 02:06 ET | 100 | 157.815 |
| 02:08 ET | 100 | 157.82 |
| 02:09 ET | 700 | 157.6975 |
| 02:11 ET | 100 | 157.71 |
| 02:13 ET | 100 | 157.67 |
| 02:15 ET | 700 | 157.52 |
| 02:20 ET | 100 | 157.71 |
| 02:26 ET | 2700 | 157.59 |
| 02:27 ET | 100 | 157.565 |
| 02:29 ET | 2500 | 157.125 |
| 02:31 ET | 200 | 156.875 |
| 02:33 ET | 100 | 156.985 |
| 02:36 ET | 100 | 157.11 |
| 02:40 ET | 100 | 156.7 |
| 02:42 ET | 507 | 156.515 |
| 02:44 ET | 326 | 156.3583 |
| 03:03 ET | 300 | 156.34 |
| 03:07 ET | 100 | 156.215 |
| 03:12 ET | 855 | 156.11 |
| 03:14 ET | 300 | 156.34 |
| 03:16 ET | 750 | 156.36 |
| 03:39 ET | 100 | 156.41 |
| 03:41 ET | 300 | 156.44 |
| 03:43 ET | 100 | 156.49 |
| 03:45 ET | 100 | 156.41 |
| 03:48 ET | 142 | 156.68 |
| 03:52 ET | 300 | 156.69 |
| 03:54 ET | 400 | 156.64 |
| 03:56 ET | 300 | 156.35 |
| 03:59 ET | 4790 | 156.36 |
Jun 4, 2024
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference, from 6:01AM ET on Tuesday Jun 04, 2024 by Dow Jones
6:01AM ET on Tuesday Jun 04, 2024 by Dow Jones
May 28, 2024
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS(TM) First in Human Study, from 8:00AM ET on Tuesday May 28, 2024 by Dow Jones
8:00AM ET on Tuesday May 28, 2024 by Dow Jones
May 24, 2024
BRUKINSA(R) Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL, from 6:00AM ET on Friday May 24, 2024 by Dow Jones
6:00AM ET on Friday May 24, 2024 by Dow Jones
May 14, 2024
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024, from 4:01PM ET on Tuesday May 14, 2024 by Dow Jones
4:01PM ET on Tuesday May 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Beigene Ltd | 16.2B | -20.7x | --- |
Biomarin Pharmaceutical Inc | 15.0B | 76.4x | --- |
United Therapeutics Corp | 12.1B | 13.0x | +8.22% |
Neurocrine Biosciences Inc | 13.4B | 37.1x | +62.04% |
Alnylam Pharmaceuticals Inc | 18.9B | -56.4x | --- |
Medpace Holdings Inc | 12.2B | 40.9x | +35.10% |
Company Information
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Contact Information
- Headquarters
- C/O Mourant Governance Services (Cayman) 94 Solaris Avenue, Camana BayGRAND CAYMAN, BEJ, Cayman Islands KY1-1108
- Phone
- 345-949-4123
- Fax
- ---
Executives
- Co-Founder, Executive Chairman of the Board, Chief Executive Officer
- John Oyler
- President, Chief Operating Officer, General Manager - China
- Xiaobin Wu
- Co-Founder, Non-Executive Director
- Xiaodong Wang
- Chief Financial Officer
- Julia Wang
- Senior Vice President, General Counsel
- Chan Lee
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $17.2B |
|---|---|
Revenue (TTM) | $2.8B |
Shares Outstanding | 104.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.60 |
EPS | $-7.57 |
Book Value | $36.95 |
P/E Ratio | -20.7x |
Price/Sales (TTM) | 6.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -26.60% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
